Desensitization With Tocilizumab and IVIg: A Prospective Controlled Cohort Study in a Predominantly Black American Population

医学 脱敏(药物) 托珠单抗 内科学 前瞻性队列研究 肾移植 队列 移植 免疫学 免疫抑制 人口 抗体 队列研究 他克莫司 人类白细胞抗原 入射(几何) 胃肠病学 封锁 外科 并发症 人口研究 抗原 肾移植 群体反应性抗体 透析 阿巴塔克普 回顾性队列研究 免疫病理学 临床意义
作者
Carly J. Amato-Menker,Stephen Rithvik Seelam,Mary Carmelle Philogene,Amber B. Paulus,Gaurav Gupta,Irfan Moinuddin
出处
期刊:Transplantation [Wolters Kluwer]
被引量:2
标识
DOI:10.1097/tp.0000000000005829
摘要

BACKGROUND: Desensitization strategies for highly sensitized kidney transplant candidates remain limited in efficacy. Tocilizumab, an interleukin-6 receptor antagonist, has been proposed as an adjunct to IVIg to reduce HLA antibody burden. METHODS: In this prospective controlled cohort study, highly sensitized candidates (median calculated panel reactive antibody [cPRA], 98.0%) were (n = 19) or were not (n = 15) treated with tocilizumab and IVIg. All tocilizumab-treated patients had failed ≥3 mo of IVIg-based desensitization. We assessed changes in cPRA, unacceptable antigens (U/As), transplant rates, and posttransplant outcomes. RESULTS: Tocilizumab-treated patients were more likely to demonstrate any reduction in cPRA during the study period (84.2% versus 33.3%; P = 0.002). Median cPRA change at nadir was -0.9% versus 0.0% (P = 0.02), although end-of-study differences were not statistically significant. Treated patients more frequently achieved removal of high-impact U/As (median cPRA of removed U/As 31.7% versus 0.0%; P = 0.004), and 3 underwent transplantation across antigens previously listed as unacceptable. Transplant rates (89.5% versus 73.3%; P = 0.4) and early posttransplant outcomes-including rejection, graft loss, BK viremia, renal function, de novo donor-specific antibody, and donor-specific antibody rebound-were similar between groups. CONCLUSIONS: In this controlled cohort, tocilizumab combined with IVIg was associated with greater reductions in HLA antibody burden without an apparent increase in early posttransplant immunologic risk. These findings support further evaluation of interleukin-6 (IL-6) blockade as an adjunctive desensitization strategy, particularly in candidates with limited transplant access despite high allocation priority.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cc完成签到,获得积分10
刚刚
xushanqi发布了新的文献求助10
刚刚
Lucas的应助被huhu采纳,获得10
刚刚
xxiang发布了新的文献求助10
1秒前
1秒前
2秒前
可爱的函函的应助被初景采纳,获得20
2秒前
英姑的应助被予秋采纳,获得10
2秒前
NexusExplorer的应助被代曼采纳,获得10
3秒前
亚亚发布了新的文献求助10
3秒前
万能图书馆的应助被王雯瑄采纳,获得10
3秒前
4秒前
4秒前
5秒前
乐乐的应助被HIT_C采纳,获得10
5秒前
科研通AI65的应助被ice采纳,获得10
5秒前
6秒前
wky完成签到,获得积分10
7秒前
7秒前
lulula完成签到,获得积分10
7秒前
9秒前
syangZ发布了新的文献求助10
9秒前
9秒前
9秒前
9秒前
Misaki完成签到,获得积分10
10秒前
10秒前
11秒前
12秒前
xi发布了新的文献求助10
12秒前
白给发布了新的文献求助10
12秒前
SUYE发布了新的文献求助10
12秒前
wwwying发布了新的文献求助10
13秒前
邹醉蓝完成签到,获得积分0
13秒前
务实的天空完成签到 ,获得积分10
13秒前
元宵发布了新的文献求助10
13秒前
今后的应助被炸毛小猫咪采纳,获得10
14秒前
希望天下0贩的0的应助被esther采纳,获得10
15秒前
123456发布了新的文献求助10
15秒前
顽石发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067